Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

Early Phase 1

Recruiting

• Conditions: Squamous Cell Cancer; Squamous Cell Carcinoma; Skin Cancer; Non-melanoma Skin Cancer
• Interventions: Drug: 30% ascorbic acid in DMSO

• Registration Number: NCT05932511
• Lead Sponsor: Center for Biomedical Research, Inc.

Brief Summary

Randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in otherwise healthy adult patients. Outcome measure was biopsy proven resolution of the carcinoma.

Detailed Description

Importance:

Skin cancer is the most common cancer in the United States, with more people diagnosed each year than all other cancers combined. Basal cell and squamous cell cancers are the most common forms with an estimated 6-7 million cases diagnosed annually. Costs of treating these cancers in the U.S. are estimated at $9-10 billion annually. Task force consensus guidelines suggest Mohs surgery as the treatment of choice, and as the single most precise and effective treatment method. However, cost and issues of cosmesis are principal disadvantages. Previous studies show the effectiveness of a topical solution of ascorbic acid in the treatment of BCC. This study extends previous work to evaluate efficacy in the treatment of SCC of the skin.

Objective:

To evaluate efficacy of a therapeutic regimen in treating squamous cell cancer, consisting of 30% ascorbic acid in 95% dimethylsulfoxide topically applied at home by patients twice a day for 8 weeks, vs 5% imiquimod cream which is an FDA approved treatment for SCC.

Design, Setting, and Participants:

This study was carried out in accordance with principles of the Declaration of Helsinki. Detailed informed consent was obtained from each patient.

Eligible participants of any age had histologically confirmed primary, previously untreated, nodular or superficial SCC. Patients with cancers larger than 2 cm or deeper than 2 mm were excluded from the study. Imiquimod was applied once daily for 5 days per week as per manufacturer instructions for treatment of SCC. Patients were randomly assigned to treatment group. Participants and outcome assessors were blinded to treatment protocol. Patients were seen at initial visit, 4 weeks, 8 weeks, and six weeks after treatment conclusion for final biopsy. The AA treatment was a solution while the IMQ a cream, however participants were simply told they would be receiving a topical treatment with instructions on how to apply, thus the blinding was intact.

Main Outcomes and Measures Number of lesions out that were cancer free after 8 wks of treatment.

Study Timeline

• Study Start: 2023-06-12
• Study First Submitted: 2023-06-21
• Study First Submitted QC: 2023-07-02
• Study First Posted: 2023-07-06
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-28
• Last Update Posted: 2023-08-30
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Presence of biopsy proven squamous cell cancer of the skin -

Exclusion Criteria

Previous history of malignancy, diabetes, immunocompromised

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
30% Ascorbic Acid in DMSO	30% ascorbic acid in DMSO	Topical application twice daily of 300ul 30% (w/v) solution of ascorbic acid in DMSO

Primary Outcome Measures

Name	Time	Method
Lesion Resolution	8 weeks	Number of lesions tumor free by 2 mm punch biopsy post treatment

Trial Locations

Locations (1)

Center for Biomedical Research,Inc.; 🇺🇸 Boise, Idaho, United States